SHW vs. GSK
SHW (The Sherwin-Williams Company) and GSK (GlaxoSmithKline plc) are both stocks. SHW operates in Specialty Chemicals (Basic Materials), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, SHW returned 13.58%/yr vs 5.35%/yr for GSK. At a 0.25 correlation, their price movements are largely independent.
Performance
SHW vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SHW achieves a -1.61% return, which is significantly lower than GSK's 9.89% return. Over the past 10 years, SHW has outperformed GSK with an annualized return of 13.58%, while GSK has yielded a comparatively lower 5.35% annualized return.
SHW
- 1D
- 0.13%
- 1M
- 6.01%
- YTD
- -1.61%
- 6M
- -3.00%
- 1Y
- -4.65%
- 3Y*
- 9.64%
- 5Y*
- 3.70%
- 10Y*
- 13.58%
GSK
- 1D
- 0.34%
- 1M
- 6.78%
- YTD
- 9.89%
- 6M
- 10.40%
- 1Y
- 34.50%
- 3Y*
- 19.84%
- 5Y*
- 5.34%
- 10Y*
- 5.35%
SHW vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SHW The Sherwin-Williams Company | -1.61% | -3.83% | 9.90% | 32.73% | -31.96% | 44.90% | 27.05% | 49.70% | -3.23% | 54.11% |
GSK GlaxoSmithKline plc | 9.89% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between SHW and GSK is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.27 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.28 |
Correlation (All Time) Calculated using the full available price history since Jul 9, 1986 | 0.25 |
Fundamentals
SHW:
$78.72B
GSK:
$108.04B
SHW:
$10.42
GSK:
£2.85
SHW:
30.45
GSK:
13.90
SHW:
2.96
GSK:
0.93
SHW:
3.31
GSK:
2.47
SHW:
17.77
GSK:
3.42
SHW:
$23.94B
GSK:
£32.78B
SHW:
$11.76B
GSK:
£23.87B
SHW:
$4.29B
GSK:
£11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SHW vs. GSK — Risk / Return Rank
SHW
GSK
SHW vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Sherwin-Williams Company (SHW) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| SHW | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.49 | ||
| Sortino ratioReturn per unit of downside risk | -2.10 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.20 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | -0.47 | 1.58 | -2.06 |
| Martin ratioReturn relative to average drawdown | -0.99 | 3.92 | -4.91 |
Loading charts...
Drawdowns
SHW vs. GSK - Drawdown Comparison
The maximum SHW drawdown since its inception was -52.02%, smaller than the maximum GSK drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for SHW and GSK.
Loading charts...
Drawdown Indicators
| SHW | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -52.02% | -55.70% | +3.68% |
Max Drawdown (1Y)Largest decline over 1 year | -21.36% | -18.63% | -2.73% |
Max Drawdown (3Y)Largest decline over 3 years | -25.69% | -28.46% | +2.77% |
Max Drawdown (5Y)Largest decline over 5 years | -42.46% | -50.10% | +7.64% |
Max Drawdown (10Y)Largest decline over 10 years | -42.46% | -50.10% | +7.64% |
Current DrawdownCurrent decline from peak | -19.53% | -11.92% | -7.61% |
Average DrawdownAverage peak-to-trough decline | -11.63% | -18.87% | +7.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.28% | 8.28% | +2.00% |
Volatility
SHW vs. GSK - Volatility Comparison
The Sherwin-Williams Company (SHW) has a higher volatility of 9.00% compared to GlaxoSmithKline plc (GSK) at 6.81%. This indicates that SHW's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SHW | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.00% | 6.81% | +2.19% |
Volatility (6M)Calculated over the trailing 6-month period | 19.26% | 18.49% | +0.77% |
Volatility (1Y)Calculated over the trailing 1-year period | 25.46% | 27.06% | -1.60% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 26.27% | 25.08% | +1.19% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 26.58% | 22.89% | +3.69% |
Dividends
SHW vs. GSK - Dividend Comparison
SHW's dividend yield for the trailing twelve months is around 1.00%, less than GSK's 3.26% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.26% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
SHW The Sherwin-Williams Company | 1.00% | 0.98% | 0.84% | 0.78% | 1.01% | 0.62% | 0.73% | 0.77% | 0.87% | 0.83% | 1.25% | 1.03% |
Financials
SHW vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between The Sherwin-Williams Company and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SHW vs. GSK - Profitability Comparison
SHW - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Sherwin-Williams Company reported a gross profit of 2.78B and revenue of 5.67B. Therefore, the gross margin over that period was 49.1%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
SHW - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Sherwin-Williams Company reported an operating income of 810.90M and revenue of 5.67B, resulting in an operating margin of 14.3%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
SHW - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Sherwin-Williams Company reported a net income of 534.70M and revenue of 5.67B, resulting in a net margin of 9.4%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
SHW and GSK have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
SHW has higher volatility (9.00%) compared to GSK (6.81%). In terms of maximum drawdown, SHW dropped -52.02% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.09 vs -0.40), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SHW and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer